Connect with us

Legal & Regulation

CannTrust Allegedly Relied on Black Market Cannabis Seeds for Production, Further Hurting its Brand



CannTrust Allegedly Relied on Black Market Cannabis Seeds for Production, Further Hurting its Rep

CannTrust has since been under the spotlight for having violated a number of rules regarding cannabis production. With their senior management witnessing a complete cleansing, followed by their supposed illegal growing and lawsuits-attached, comes more news as to what has been going on within the walls of the Canadian medical cannabis provider.

Turns out, that the firm has been using black market cannabis seeds in its production reports BNN Bloomberg. It doesn’t end there! Interestingly, the firm’s employees have altered the names of nearly 20 strains so that it would match what the firm is legally licensed to grow – and to add to it, nearly 20% of these employees have already been laid off.

Nearly 1000 grown plants flourished in using illegally-source strains. The question still remains as to how much of the plants were actually delivered to the legal markets, now that it is clear that the firm may have been participating in the black markets as well.

As per unnamed sources, the company had to up their production in order to meet the deals established with distributors and other producers. BNN Bloomberg was the first to have reported on this matter, and they seem to have gotten hold of spokesperson, Jane Shapiro, who was referenced saying:

“To the best of our knowledge, no product using seeds from unauthorized external sources was introduced into the market.”

When it comes to the possible charges, Health Canada supposedly shared with BNN Bloomberg that selling illegal cannabis can result in anything between a fine to 14 years of prison time. In the case of CannTrust, the firm is currently slapped with a warning letter, a one million dollar fine and a license that has been revoked.

This creates a domino effect in which the firm’s stock continues to witness a drop in value. Given all the allegations and poor stock performance, the news outlet disclosed that it may be removed from the S&P/TSX composite as early as this month.

Then comes employees, with the firm having slashed its team by 20 percent. The Interim CEO, Robert Marcovitch, has since publicized that the overall restructure in their workforce was crucial amidst their “current requirements of [their] business,” adding that,

“These changes also position the company to better serve our patients and customers with high quality, innovative products.”

Michael is a freelance writer with several years of experience in writing of all kinds. From the uber-technical to the more relaxed, he is well-versed in a variety of styles. Lately, his work has been primarily focused on the CBD industry—a market with which he has a particular background and interest. Michael has an extensive interest and experience in legal research for the CBD market, and he has a knack for well-researched pieces and guides for the growing CBD and medicinal cannabis community.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.